Infection Control Today: How Can Physical Medicine and Rehabilitation Help COVID Long-Haulers?
June 7, 2023
Monica Verduzco-Gutierrez, MD, professor and chair, Rehabilitation Medicine, was interviewed for this story. Watch Now
June 7, 2023
Monica Verduzco-Gutierrez, MD, professor and chair, Rehabilitation Medicine, was interviewed for this story. Watch Now
June 1, 2023
March 22, 2021, is a day Belinda Trevino Scholz will never forget. “I was outside doing yard work and came inside,” she said. “Suddenly, I got this massive headache on my right side that went from my head to my toes.” She called a nurse friend who told her to rush to the […]
May 25, 2023
From social media to ads featuring an earworm jingle, it’s hard to escape hearing about Ozempic. Hailed for its game-changing effect on diabetes and obesity, semaglutide, the generic medication sold under the brand name Ozempic, is now being studied for its effectiveness on another deadly disease — Alzheimer’s. The Glenn Biggs Institute for Alzheimer’s and […]
May 24, 2023
Andrew Brenner, MD, Neurosurgery, and William Kelly, MD, Hematology & Oncology, both of the UT Health San Antonio Mays Cancer Center, were mentioned in this story via the word ‘conducted,’ which links to the university’s press release about the Mays Cancer Center conducting the only clinical trial in America of a specific drug combination for […]
May 23, 2023
An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer […]
May 23, 2023
An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 23, 2023) — The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma […]